Skip Ribbon Commands
Skip to main content
Dr Khor Li Yan

Dr Khor Li Yan

​MBBCh, Diplomate in American Board of Pathology in Cytology, Diplomate American Board of Pathology (Anatomic and Clinical)

Senior Consultant

Singapore General Hospital

Specialty: Pathology

Sub-specialties: Histopathology, Cytology

Clinical Appointments

  • Senior Consultant Anatomical Pathology Singapore General HospitalSingapore General Hospital


Dr Khor received her medical degree from the Royal College of Surgeons in Ireland. She spent several years in post-doctoral translational research on prostate cancer with the Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. She completed anatomical and clinical pathology residency at Case Western Reserve University School of Medicine in Cleveland, Ohio in 2012, followed by cytology fellowship training at the Cleveland Clinic Foundation in 2013. She remained as faculty the following year while pursuing a mini-fellowship in genitourinary pathology.


  • 2013 Diplomate of the American Board of Pathology, Cytopathology 
  • 2012 Diplomate of the American Board of Pathology, Anatomic and Clinical Pathology 
  • 1998 MBBCh, BAO (NUI), LRCP & SI

Professional Appointments and Committee Memberships

  • Adjunct Assistant Professor, Duke-NUS Medical School 
  • Faculty Member, Pathology Residency Program, SingHealth 
  • Association of Pathologists, Singapore (Singapore Division of the IAP) (Member) 
  • Society of Cytology, Singapore (Member) 
  • Singapore Medical Association (Member) 
  • American Society of Cytopathology (Member) 
  • United States and Canadian Academy of Pathology (Regular Member) 
  • International Society of Urological Pathology (Member) 
  • College of American Pathologists (Fellow) 
  • American Society for Clinical Pathology (Fellow)


  • ​2012 American Society of Cytopathology, 60th ASC Annual Scientific Meeting Travel Scholarship 
  • 2012 American Society of Cytopathology, ‘Innovative Methods for Delivery of Continuing Education for Cytopathology’ Essay Fellow Category Award Winner 
  • 2010 International Society of Urological Pathology Stipend Award 

Research Interests

  • Urologic pathology and cytopathology
  • Tumour biomarkers
  • Circulating Tumour Cells (CTC) Core
  • Precision histology using deep learning


  • Yeong J, Sultana R, Teo J, Huang HH, Yuen J, Tan PH, Khor LY. Gleason grade grouping of prostate cancer is of prognostic value in Asian men. J Clin Pathol. 2017 Mar 13. pii: jclinpath-2016-204276. doi: 10.1136/jclinpath-2016-204276. [Epub ahead of print]
  • Pollack A, Kwon D, Walker G, Khor LY, Horowitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumour Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. J Natl Cancer Inst (2017) 109 (2): 1-8. Published: 14 February 2017.
  • Khor LY, Dakal H, Reynolds JP, et al. Tumour Necrosis Adds Prognostically Significant Information to ISUP Grade for Clear Cell Renal Cell Carcinoma. A Study of 842 Consecutive Localized Cases from a Single Institution. Am J Surg Pathol 2016 Sep;40(9):1224-31.
  • Dakal H, McKenney J, Khor LY, et al. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma And Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study Of 37 Cases From A Single Institution. Am J Surg Pathol. 2016 Feb;40(2):141-54.
  • Khor LY, Tan PH. Diagnostic Biomarkers In Eosinophilic Renal Neoplasms. Urol Clin North Am. 2016 Feb;43(1):87-94.
  • Khor LY, Abdul-Karim FW, Bruening A, Weber D, Booth CN. Papanicolaou Tests with Coexisting Squamous and Glandular Lesions. Cancer Cytopathol. 2014 Aug;122(8):620-6.
  • Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation Of MDM2, p16, And p53 Staining Levels As Biomarkers Of Biochemical Recurrence Following Salvage Radiation Therapy For Recurrent Prostate Cancer. Prostate 2012 Dec 1;72(16):1757-66.
  • Hensley H, Hannoun-Levi J, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, Pollack A. PKA Knockdown Enhances Cell Killing In Response To Radiation And Androgen Deprivation. Int J Cancer 2011 Feb 15;128(4):962-73.
  • Xu X, Garcia MV, Li T, Khor LY, Gajapathy RS, Spittle C, Weed S, Lessin S, Wu H. Cytoskeleton Alterations In Melanoma: Aberrant Expression Of cortactin, An Actin-binding Adaptor Protein, Correlates With Melanocytic Tumor Progression. Mod Path 2010 Feb;23(2):187-96.
  • Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond EH, Venketesan V, Byhardt R, Asbell S, Shipley W, Sandler H. The Importance Of Protein Kinase-A In Prostate Cancer - Relationship To Patient Outcome In RTOG 92-02. Clin Cancer Res 2009 Sep1;15(17):5478-84.
  • Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond MEH, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 And Ki-67 Predict For Distant Metastasis And Mortality In Men Treated With Radiotherapy And Androgen Deprivation For Prostate Cancer: An Analysis Of RTOG 92-02. J of Clin Oncol 2009 July 1; 27(19):3177-3184.
  • Khor LY, Bae K, DeSilvio M, Al-Saleem T, Hammond MEH, Grignon DJ, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A. Protein Kinase A RI-alpha (PKA-RIa) Predicts Prostate Cancer Outcome: An Analysis Of Radiation Therapy Oncology Group Trial 86-10. Int  J  Radiat  Oncol  Biol  Phys  2008 Aug 1; 71(5):1309-15.
  • Khor LY, Bae K, Hammond ME, Pollack A, Venkatesan V, Rosenthal S, Sandler H, Hanks GE, Shipley WU, Dicker AP. Cox-2 Overexpression Predicts Prostate Cancer Outcome: An Analysis Of RTOG 92-02. Lancet Oncol 2007; 8:912-920.
  • Stoyanova R, Hachem P, Hensley H, Khor LY, Mu Z, Hammond ME, Agrawal S, Pollack A. Antisense MDM2 Sensitizes LNCaP Prostate Cancer Cells To Androgen Deprivation, Radiation And The Combination In Vivo. Int J Radiat Oncol Biol Phys 2007 Jul 15; 68(4):1151-60.
  • Khor LY, Moughran J, Al-Saleem T, Hammond MEH, Venkatesan V, Rosenthal S, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A. Bcl-2 And Bax Predict Prostate Cancer Outcome In Men Treated With Androgen Deprivation And Radiotherapy On RTOG 92-02. Clin Cancer Res 2007 Jun 15; 13(12):3585-90.
  • Chakravarti A, Desilvio M, Zhang M, Grignon D, Rosenthal SA, Asbell S, Hanks G, Sandler H, Khor LY, Pollack A, Shipley W. The Prognostic Value Of p16 In Locally Advanced Prostate Cancer: A Study Based On RTOG 9202. J of Clin Oncol 2007 Jul 20; 25(21):3082-9.
  • Torres-Roca JF, DeSilvio M, Mora-Diaz LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, Pollack A. Activated Stat3 As A Correlate Of Distant Metastasis In Prostate Cancer: A Secondary Analysis Of Radiation Therapy Oncology Group 8610. Urology 2007 Mar; 69(3):505-9.
  • Khor LY, DeSilvio M, Li R, McDonnell TJ, Hammond ME, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A. Bcl-2 And Bax Expression And Prostate Cancer Outcome In Men Treated With Radiotherapy In Radiation Therapy Oncology Group Protocol 86-10. Int J Radiat Oncol Biol Phys 2006 Sep 1; 66(1):25-30.
  • Khor LY, DeSilvio M, Al-Saleem T, Hammond ME, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A. MDM2 As A Predictor Of Prostate Cancer Outcome: An Analysis Of RTOG 8610. Cancer 2005 Sep 1; 104(5):962-7.
  • Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Byhardt R, Roach III M, Lawton CA, Hanks GE, Shipley WU,  Sandler HM. Ki-67 Staining Is A Strong Predictor Of Patient Outcome For Prostate Cancer Patients Treated With Androgen Deprivation Plus Radiotherapy: An Analysis Of RTOG 92-02. J Clin Oncol 2004 Jun 1; 22 (11): 2133-40.

Research Trials